Navigation Links
Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device
Date:12/16/2009

(Aarhus, Denmark, December 14, 2009) Unisense FertiliTech A/S has received a further 1.6 million Euro in capital funding to scale up production and support of the EmbryoScope™ Embryo Monitoring System in order to meet the rapidly growing demand for this promising new technology. The capital was invested by LD Pensions and Unisense A/S that continue to own each about 50% of the company.

Aarhus, Denmark (PRWEB) December 16, 2009 -- Unisense FertiliTech A/S has received a further 1.6 million Euro in capital funding to scale up production and support of the EmbryoScope™ Embryo Monitoring System in order to meet the rapidly growing demand for this promising new technology. The capital was invested by LD Pensions and Unisense A/S that continue to own each about 50% of the company.

During IVF treatment, multiple oocytes are removed from the patient and fertilized in-vitro. The resulting fertilized eggs are allowed to develop for a period of 2 to 5 days, before the embryologist must select the best potential embryo or embryos to transfer back to the patient. Ideally, a single embryo resulting in a single pregnancy is optimal as multiple pregnancies present risks to both maternal and fetal health.

A major challenge for the embryologist is determining which embryos have the best potential to create a single healthy baby. The EmbryoScope® Embryo Monitoring System allows uninterrupted time-lapse observation of embryo development in a stable controlled incubation environment. Embryo quality parameters can be assessed and reviewed without the potentially damaging effects of removing the embryo from a stable controlled environment.

CEO Jens Gundersen says they are encouraged with the overwhelming response to the initial sales launch of the instrument, and that with the additional capital, FertiliTech will be able to scale up production to meet the demands of the rapidly expanding interest for the EmbryoScope® Embryo monitoring system.

Unisense FertiliTech A/S is a Danish company which was founded in 2003, as a daughter company of Unisense A/S. The company develops and manufactures instruments and analysis solutions to facilitate in-vitro Fertilization. The company is highly research oriented and is currently involved in various international research projects involving improved embryo selection and analysis, embryo respiration and stem cell research.

Contact Person:
Francesca Bahr
Sales and Marketing Manager
Unisense FertiliTech A/S
Phone Number +45 89449525
Mobile Phone: +45 40255538

Jens K. Gundersen
CEO
+45 21601675

Email Address fab (at) fertilitech (dot) com
Website URL http://www.fertilitech.com

###

Read the full story at http://www.prweb.com/releases/2009/12/prweb3339374.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Increased distance to physician associated with thicker skin cancer at diagnosis
2. Methamphetamine study suggests increased risk for HIV transmission
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Minorities more likely to have sleep durations associated with increased mortality
5. Teens who see more smoking in movies may have increased risk of becoming established smokers
6. Study shows adverse drug events reported to the FDA have significantly increased
7. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
8. Maternal depression and controlling behavior associated with increased stress response in infants
9. BioProcessors Launches SimCell(TM) Services to Meet Increased Customer Demand
10. Both short and long sleep is associated with increased mortality
11. New Study Shows Lower Costs, Increased Consumer Engagement in Account-Based Health Plans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... Michigan (PRWEB) , ... January 24, 2017 , ... The ... other advocates for drug and alcohol awareness, have worked with communities to designate the ... year, observed January 23-29, 2017, the theme is “Shatter the Myths.” As a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... localization services for life science companies, has achieved ISO 17100:2015 certification following ... America. ISO 17100 is the globally recognized standard that establishes guidance for ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology: